Cyteir Therapeutics, Inc. (CYT): Price and Financial Metrics

Cyteir Therapeutics, Inc. (CYT): $3.02

0.07 (-2.27%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add CYT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#84 of 360

in industry

CYT Price/Volume Stats

Current price $3.02 52-week high $3.19
Prev. close $3.09 52-week low $1.48
Day low $3.00 Volume 1,006,800
Day high $3.09 Avg. volume 190,462
50-day MA $3.09 Dividend yield N/A
200-day MA $2.86 Market Cap 108.71M

CYT Stock Price Chart Interactive Chart >


Cyteir Therapeutics, Inc. (CYT) Company Bio


Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.


CYT Latest News Stream


Event/Time News Detail
Loading, please wait...

CYT Latest Social Stream


Loading social stream, please wait...

View Full CYT Social Stream

Latest CYT News From Around the Web

Below are the latest news stories about CYTEIR THERAPEUTICS INC that investors may wish to consider to help them evaluate CYT as an investment opportunity.

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

LEXINGTON, Mass., October 12, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine in Platinum-Resistant Ovarian Cancer" (Poster: LB_A13) at the 2023

Yahoo | October 12, 2023

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution

LEXINGTON, Mass., June 30, 2023--Cyteir Therapeutics, Inc. ("Cyteir" or the "Company") (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir’s Board of Directors has determined, after consideration of potential strategic alternatives, it is in the best interests of its shareholders to dissolve Cyteir, liquidate its assets following an orderly wind down of the Company’s operations, and return

Yahoo | June 30, 2023

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

LEXINGTON, Mass., June 03, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors" (Abstract: 3099, Poster: 297) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting i

Yahoo | June 3, 2023

Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

LEXINGTON, Mass., May 10, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent operational highlights.

Yahoo | May 10, 2023

Insiders who bought Cyteir Therapeutics, Inc. (NASDAQ:CYT) last year must be regretting not buying more as market cap hits US$72m

Cyteir Therapeutics, Inc. ( NASDAQ:CYT ) insiders who purchased shares in the last 12 months were richly rewarded last...

Yahoo | April 20, 2023

Read More 'CYT' Stories Here

CYT Price Returns

1-mo -2.89%
3-mo -0.66%
6-mo 6.34%
1-year 67.78%
3-year N/A
5-year N/A
YTD -0.66%
2023 84.24%
2022 -85.49%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!